

Kartik Anand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9326498/publications.pdf>

Version: 2024-02-01

23
papers

363
citations

933264

10
h-index

887953

17
g-index

24
all docs

24
docs citations

24
times ranked

492
citing authors

#	ARTICLE	IF	CITATIONS
1	Osimertinib-Induced Cardiotoxicity. <i>JACC: CardioOncology</i> , 2019, 1, 172-178.	1.7	66
2	A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. <i>Science Translational Medicine</i> , 2021, 13, eabj5070.	5.8	48
3	Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. <i>ESMO Open</i> , 2020, 5, e000866.	2.0	34
4	Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 856.	1.7	31
5	Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2020, 21, 437-442.	1.1	26
6	T-cell lymphoma secondary to checkpoint inhibitor therapy. , 2020, 8, e000104.		25
7	A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 199-204.	1.1	23
8	Mycobacterial Infections With Ruxolitinib: A Retrospective Pharmacovigilance Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 18-23.	0.2	22
9	Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2021, 44, 132-139.	1.2	19
10	Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 20.	1.0	19
11	Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2021, 11, 82.	1.6	16
12	Global Ophthalmology Practice Patterns during COVID-19 Pandemic and Lockdown. <i>Ophthalmic Epidemiology</i> , 2022, 29, 233-244.	0.8	10
13	Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Cancer. <i>American Journal of Clinical Pathology</i> , 2018, 150, S143-S143.	0.4	5
14	Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy. <i>Current Oncology Reports</i> , 2022, 24, 475-491.	1.8	4
15	Primary diffuse large B-cell lymphoma of the uterus. <i>Medicine (United States)</i> , 2021, 100, e27359.	0.4	3
16	Complete Response to R-EPOCH in Primary Cardiac Lymphoma. <i>Case Reports in Hematology</i> , 2019, 2019, 1-4.	0.3	2
17	Acute myeloid leukemia with eosinophilia after cyclin-dependent kinases 4/6 inhibitor treatment due to underlying clonal hematopoiesis of indeterminate potential. <i>American Journal of Hematology</i> , 2019, 94, E82-E85.	2.0	2
18	Cardiac Failure Because of Osimertinib. <i>Journal of Clinical Oncology</i> , 2021, 39, 2049-2050.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Is a liver-spleen scan helpful in the evaluation of patients with thrombocytopenia?. Annals of Hematology, 2015, 94, 1921-1922.	0.8	1
20	Autosplenectomy in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH). Case Reports in Hematology, 2019, 2019, 1-5.	0.3	1
21	Four Limb Ischemia: A Severe Case of Heparin Induced Thrombocytopenia. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 397-398.	0.3	1
22	Radiation therapy in primary mediastinal large Bâ€cell lymphoma treated with DAâ€EPOCH. Clinical Case Reports (discontinued), 2020, 8, 1153-1155.	0.2	0
23	Cardiac dysfunction due to Osimertinib. Lung Cancer, 2021, 153, 193-194.	0.9	0